1990
DOI: 10.1016/s0272-2712(18)30572-9
|View full text |Cite
|
Sign up to set email alerts
|

Nephrotoxic and Ototoxic Agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

2
22
1
1

Year Published

1998
1998
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 39 publications
(26 citation statements)
references
References 98 publications
2
22
1
1
Order By: Relevance
“…Dysfunctions at the level of the stria vascularis may result in a massive entry of aminoglycosides into the inner-ear fluid. 32 Thus, the effect of loop diuretics on the stria vascularis facilitates the toxic effects of aminoglycosides on the hair cells. Similarly, ethacrynic acid is known to interact with cisplatin to increase its ototoxic effects.…”
Section: Introductionmentioning
confidence: 99%
“…Dysfunctions at the level of the stria vascularis may result in a massive entry of aminoglycosides into the inner-ear fluid. 32 Thus, the effect of loop diuretics on the stria vascularis facilitates the toxic effects of aminoglycosides on the hair cells. Similarly, ethacrynic acid is known to interact with cisplatin to increase its ototoxic effects.…”
Section: Introductionmentioning
confidence: 99%
“…Unfortunately, numerous drugs used to treat life-threatening illnesses are known to damage hair cells (Walker et al, 1990;Raphael, 2002). For example, hearing impairment can result from use of chemotherapeutic agents, such as cisplatin for cancer patients, or from treatment with aminoglycoside antibiotics for patients with bacterial infections such as meningitis, encephalitis, tuberculosis, and for patients with large wounds (Stone et al, 1996;Walker et al, 1990;Peters et al, 2003;Matsui and Cotanche, 2004). Thus, there is a need to develop methods to regenerate sensory cells and to develop protective therapeutic strategies for use with ototoxic drugs.…”
Section: Introductionmentioning
confidence: 99%
“…Gentamicin has been used in preliminary clinical trials in patients with Duchenne muscular dystrophy and cystic fibrosis caused by nonsense mutations [15,16]. However, the high doses that are required, side-effects such as nephrotoxicity and ototoxicity and need for intravenous or intramuscular administration have limited its potential usefulness for treatment of human diseases [17]. Studies with the novel aminoglycosides NB30, NB54 and NB84 that exhibit significantly reduced toxicity and superior readthrough efficiency than that of gentamicin are ongoing [18][19][20].…”
Section: Discussionmentioning
confidence: 99%